Orphanet: Ricerca semplice

Cerca una sperimentazione clinica

Altra/e opzione/i di ricerca

268 Risultato/i

Sperimentazioni cliniche nazionali

SENSCIS(R)-ON: An Open-label Extension Trial of the Long Term Safety of Nintedanib in Patients With 'Systemic Sclerosis Associated Interstitial Lung Disease' (SSc-ILD) (Phase 3) - AT Institution: Information not provided - AT

Systems medicine analysis of sarcoidosis by targeting mTOR in a pilot study of sirolimus as treatment in patients with sarcoidosis (phase 2) Institution: Information not provided - AT

A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) - BE Cliniques Universitaires de Bruxelles - Hôpital Erasme Service de Pneumologie

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants with Pulmonary Fibrosis - BE Cliniques universitaires Saint-Luc - UCLouvain Service de pneumologie

SENSCISTM-ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) - BE Ghent University Hospital - UZ Gent Department of Rheumatology

SENSCISTM- ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD)-CA Institution: Information not provided - CA

Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis -FI- Turku University Hospital Turku PET CENTRE

AVADIS: Impact of Transcutaneous Auricular Vagus Nerve Stimulation on Digestive Symptoms in Systemic Sclerosis -FR CHU Grenoble Alpes - Site Nord - Hôpital Couple Enfant Clinique Universitaire de Médecine Vasculaire

SARCOLOWDOSE : Ultra-low Dose CT Scan and MRI in Thoracic Sarcoidosis CHU de Rennes - Hôpital Pontchaillou Service de Radiologie et imagerie médicale - Imagerie thoracique et cardio-vasculaire

An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients With Relapsed or Refractory Light-Chain (AL) Amyloidosis Who Require Further Treatment - FR Institution: Information not provided - FR

A phase 2 study of Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis -FR Institution: Information not provided - FR

Safety and efficacy of itacitinib in adults with systemic sclerosis: a phase II, randomized, controlled trial - SCLERITA - SCLERITA Institution: Information not provided - FR

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Dermatomyositis -FR Institution: Information not provided - FR

EMERALD: A Two-cohort, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, PK and PD, of Emapalumab in Children and Adults With MAS in Still's Disease or With MAS in Systemic Lupus Erythematous -FR Institution: Information not provided - FR

ITAC: Multicenter, Randomized, Prospective Trial Comparing the Efficacy and Safety of Infliximab to That of Cyclophosphamide in Severe Behçet's Disease. AP-HP.Sorbonne Université - Hôpital de la Pitié-Salpêtrière Département de Médecine Interne et Immunologie Clinique (DMIIC)

COLCHI-RESIST: Study Of Colchicine Resistance In Familial Mediterranean Fever. Groupe hospitalier AP-HP.6 - Hôpital Tenon Service de médecine interne

AmyDara: A Multicentre Open Label Phase II Study of Daratumumab in AL Amyloidosis Patients Not in VGPR or Better - FR CHU de Limoges - Hôpital Dupuytren Service d'hématologie clinique et de thérapie cellulaire

AMYLCAR : Assessment of Cardiac Fixation During Positron Emission Tomography (PET) Examination Using 18F-Flutemetamol (Vizamyl ®) Within Amyloid Cardiac Injuries (Phase I) CHU de Toulouse - Hôpital Pierre-Paul Riquet Service de Médecine nucléaire

ADUSE: Subcutaneous Injections of Autologous Cultured Adipose-derived Stroma/ Stem Cells to Heal Refractory Ischemic Digital Ulcers in Patients With Scleroderma. CHU de Toulouse - Hôpital Rangueil Service de Médecine interne et immunologie clinique

SCLERADEC III : SCLERoderma and Adipose-DErived Stroma Cells (Phase II) CHU de Marseille - Hôpital Nord Service de Médecine Interne

An open-label, phase 1/2 study of melflufen and dexamethasone for patients with al amyloidosis following at least one prior line of therapy - DE Zentrum für Innere Medizin (Krehl-Klinik) Medizinische Klinik V - Hämatologie, Onkologie und Rheumatologie

ReDox: A Randomized Phase II/III Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy - DE Zentrum für Innere Medizin (Krehl-Klinik) Medizinische Klinik V - Hämatologie, Onkologie und Rheumatologie

A phase 2 study of Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis -DE Zentrum für Innere Medizin (Krehl-Klinik) Medizinische Klinik V - Hämatologie, Onkologie und Rheumatologie

PRESIDIO: A Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients with Active Polymyositis or Dermatomyositis Institution: Information not provided - DE

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Dermatomyositis - DE Institution: Information not provided - DE

EMERALD: A Two-cohort, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, PK and PD, of Emapalumab in Children and Adults With MAS in Still's Disease or With MAS in Systemic Lupus Erythematous - DE Institution: Information not provided - DE

The RECLAIIM Study: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM) - DE Charité - Universitätsmedizin Berlin

wiRASSc: Influence of serial locoregional water-filtered infrared A radiation in addition to a multimodal standard therapy for systemic sclerosis and Raynaud's syndrome of the hands Kerckhoff-Klinik GmbH Abteilung für Rheumatologie und klinische Immunologie

SENSCIS (TM) Extension: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) - DE Medizinische Hochschule Hannover Klinik für Pneumologie

The RECLAIIM Study: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM) - DE Universitätsklinikum Essen Klinik für Neurologie

The RECLAIIM Study: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM) - DE Universitätsklinikum Köln

The RECLAIIM Study: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM) - DE Universitätsklinikum Münster

A Phase II/III, randomized, double-blind, placebo-controlled study and open active-treatment extension study to assess the efficacy and safety of the branch chain amino acids (BCAAs) in polymyositis and dDermatomyositis. Institution: Information not provided - JP

Randomized, double-blind, parallel group comparison trial of Tocilizumab for colchicine-resistant familial Mediterranean fever Institution: Information not provided - JP

Clinical trial of rituximab in interstitial lung disease secondary to systemic sclerosis Institution: Information not provided - JP

SENSCISTM- ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) - IE St. Vincent's University Hospital CF Clinic

EYEGUARD-B: A Randomized, Double-masked, Placebo-controlled Study of the Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (Phase III) Institution: Information not provided - IT

Studio di fase 1/2 in aperto su Melflufen e Desametasone in pazienti con Amiloidosi AL che seguono almeno una precedente linea di terapia - IT Institution: Information not provided - IT

Studio multicentrico di fase 2/3, in doppio cieco, randomizzato, controllato con placebo, a gruppi paralleli per valutare l'efficacia e la sicurezza di ravulizumab in partecipanti adulti affetti da dermatomiosite Institution: Information not provided - IT

Studio di Fase III nella Dermatomiosite giovanile all'esordio: prednisone verso prednisone più ciclosporina verso prednisone più metotrexate IRCCS Istituto G. Gaslini - Ospedale Pediatrico U.O. Pediatria II

Studio multicentrico randomizzato di fase III del Melphalan e Dexamethasone (MDex) vs Bortezomib, Melphalan e Dexamethasone (BMDex) nel trattamento di pazienti con Amiloidosi. Fondazione IRCCS Policlinico San Matteo Laboratorio di Biotecnologie e Tecnologie Biomediche

Studio randomizzato di fase II/III di doxiciclina rispetto alla terapia di supporto standard nei pazienti con amiloidosi cardiaca AL di nuova diagnosi sottoposti a terapia a base di bortezomib - IT Fondazione IRCCS Policlinico San Matteo Dipartimento di Medicina Molecolare

ASTIS: Sperimentazione multicentrica di trapianto autologo di cellule staminali in pazienti affetti da Sclerodermia (Fase III) AOU Careggi Dipartimento di Biomedicina

IMMEDIATE: Intravenous immunoglobulins as early treatment in newly diagnosed idiopathic inflammatory myopathies: a pilot study Amsterdam UMC, locatie AMC Afdeling Neurologie

A Phase II, Randomized, Multi-center, Placebo-controlled, Double-blind Study to Investigate the Safety of GS-248, and Efficacy on Raynaud's Phenomenon (RP) and Peripheral Vascular Blood Flow, in Subjects With Systemic Sclerosis (SSc) - NL Institution: Information not provided - NL

The MANUS Trial: Mesenchymal Stromal Cells for Angiogenesis and Neovascularisation in Digital Ulcers of Systemic Sclerosis (Phase II) UMC Utrecht - Universitair Medisch Centrum Utrecht Afdeling Nefrologie

EYEGUARD-B: A Randomized, Double-masked, Placebo-controlled Study of the Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (Phase III) - PT Institution: Information not provided - PT

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Dermatomyositis -GB Institution: Information not provided - GB

RBHIPF004 - A randomized, double blind controlled trial comparing rituximab against intravenous cyclophosphamide in connective tissue disease associated interstitial lung disease National Heart and Lung Institute, Imperial College, Royal Brompton Campus Interstitial Lung Disease Unit

SENSCISTM- ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD)GB Institution: Information not provided - UK

An open-label, phase 1/2 study of melflufen and dexamethasone for patients with al amyloidosis following at least one prior line of therapy - ES Hospital Clínic de Barcelona Servicio de Hematología

RECLAIIM: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM) -ES Institution: Information not provided - ES

Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis -ES Institution: Information not provided - ES

AFFIRM-AL: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis - ES Institution: Information not provided - ES

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Dermatomyositis -ES Institution: Information not provided - ES

VALOR: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults with Dermatomyositis -ES Institution: Information not provided - ES

An open label, long-term extension study to investigate the safety of PF-06823859 administered to adult participants >=18 and <=80 with active dermatomyositis -ES Hospital Universitario 12 de Octubre

A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis - US University of Pennsylvania Perelman School of Medicine

Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis Institution: Information not provided - US

A Phase II Multi-center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation With Post Transplant Maintenance for the Treatment of Systemic Sclerosis University of Washington

EMERALD: A Two-cohort, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, PK and PD, of Emapalumab in Children and Adults With MAS in Still's Disease or With MAS in Systemic Lupus Erythematous - SE Institution: Information not provided - SE

EYEGUARD-B: A Randomized, Double-masked, Placebo-controlled Study of the Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (Phase III) - TN Institution: Information not provided - TN

EYEGUARD-B: A Randomized, Double-masked, Placebo-controlled Study of the Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (Phase III) - TR Institution: Information not provided - TR

A Multi-centre, Double-blind, Placebo Controlled, Proof of Concept Study to Evaluate the Efficacy and Tolerability of BAF312 in Patients With Polymyositis Institute of Genomic Medicine and Rare Disorders, Semmelweis University Genetics Laboratory

A Double-blind, Randomised, Placebo-controlled Trial Evaluating the Effect of BI 655064 Administered as Sub-cutaneous Injections, on Renal Response After One Year of Treatment, in Patients With Active Lupus Nephritis (Phase 2) - AT Institution: Information not provided - AT

BRAVE I: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus - AT Institution: Information not provided - AT

SLE-BRAVE-X: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE) - AT Institution: Information not provided - AT

SELECT-GCA: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Giant Cell Arteritis (Phase 3) - AT Institution: Information not provided - AT

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Giant Cell Arteritis (Phase 3) - AT Institution: Information not provided - AT

PHOENYCS GO: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus (Phase 3) - AT Institution: Information not provided - AT

A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis (Phase 2) - AT Institution: Information not provided - AT

A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Efavaleukin Alfa in Subjects with Active Systemic Lupus Erythematosus With Inadequate Response to Standard of Care Therapy - AT Institution: Information not provided - AT

A Phase II, randomised, placebo-controlled, double-blind, parallel-group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with early progressive diffuse cutaneous systemic sclerosis - AT Institution: Information not provided - AT

GOOD-IDES: An Open-Label Phase II Study in Anti-GBM Disease (Goodpasture's Disease) With Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS - AT Allgemeines Krankenhaus der Stadt Wien Klinische Abteilung für Nephrologie und Dialyse

A Phase 2, Randomized, Double-blind Placebo-controlled Study to Test the Efficacy and Safety of KPL-301 in Giant Cell Arteritis - BE Institution: Information not provided - BE

NOVESA study: A Phase 2a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, and tolerability of orally administered GLPG1690 for 24 weeks in subjects with systemic sclerosis - BE Ghent University Hospital - UZ Gent Department of Rheumatology

SENSCIS(R)-ON: An Open-label Extension Trial of the Long Term Safety of Nintedanib in Patients With 'Systemic Sclerosis Associated Interstitial Lung Disease' (SSc-ILD) (Phase 3) - AT
Institution: Information not provided - AT

Systems medicine analysis of sarcoidosis by targeting mTOR in a pilot study of sirolimus as treatment in patients with sarcoidosis (phase 2)
Institution: Information not provided - AT

A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) - BE
Cliniques Universitaires de Bruxelles - Hôpital Erasme

Service de Pneumologie

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants with Pulmonary Fibrosis - BE
Cliniques universitaires Saint-Luc - UCLouvain

Service de pneumologie

SENSCISTM-ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) - BE
Ghent University Hospital - UZ Gent

Department of Rheumatology

SENSCISTM- ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD)-CA
Institution: Information not provided - CA

Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis -FI-
Turku University Hospital

Turku PET CENTRE

AVADIS: Impact of Transcutaneous Auricular Vagus Nerve Stimulation on Digestive Symptoms in Systemic Sclerosis -FR
CHU Grenoble Alpes - Site Nord - Hôpital Couple Enfant

Clinique Universitaire de Médecine Vasculaire

SARCOLOWDOSE : Ultra-low Dose CT Scan and MRI in Thoracic Sarcoidosis
CHU de Rennes - Hôpital Pontchaillou

Service de Radiologie et imagerie médicale - Imagerie thoracique et cardio-vasculaire

An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients With Relapsed or Refractory Light-Chain (AL) Amyloidosis Who Require Further Treatment - FR
Institution: Information not provided - FR

A phase 2 study of Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis -FR
Institution: Information not provided - FR

Safety and efficacy of itacitinib in adults with systemic sclerosis: a phase II, randomized, controlled trial - SCLERITA - SCLERITA
Institution: Information not provided - FR

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Dermatomyositis -FR
Institution: Information not provided - FR

EMERALD: A Two-cohort, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, PK and PD, of Emapalumab in Children and Adults With MAS in Still's Disease or With MAS in Systemic Lupus Erythematous -FR
Institution: Information not provided - FR

ITAC: Multicenter, Randomized, Prospective Trial Comparing the Efficacy and Safety of Infliximab to That of Cyclophosphamide in Severe Behçet's Disease.
AP-HP.Sorbonne Université - Hôpital de la Pitié-Salpêtrière

Département de Médecine Interne et Immunologie Clinique (DMIIC)

COLCHI-RESIST: Study Of Colchicine Resistance In Familial Mediterranean Fever.
Groupe hospitalier AP-HP.6 - Hôpital Tenon

Service de médecine interne

AmyDara: A Multicentre Open Label Phase II Study of Daratumumab in AL Amyloidosis Patients Not in VGPR or Better - FR
CHU de Limoges - Hôpital Dupuytren

Service d'hématologie clinique et de thérapie cellulaire

AMYLCAR : Assessment of Cardiac Fixation During Positron Emission Tomography (PET) Examination Using 18F-Flutemetamol (Vizamyl ®) Within Amyloid Cardiac Injuries (Phase I)
CHU de Toulouse - Hôpital Pierre-Paul Riquet

Service de Médecine nucléaire

ADUSE: Subcutaneous Injections of Autologous Cultured Adipose-derived Stroma/ Stem Cells to Heal Refractory Ischemic Digital Ulcers in Patients With Scleroderma.
CHU de Toulouse - Hôpital Rangueil

Service de Médecine interne et immunologie clinique

SCLERADEC III : SCLERoderma and Adipose-DErived Stroma Cells (Phase II)
CHU de Marseille - Hôpital Nord

Service de Médecine Interne

An open-label, phase 1/2 study of melflufen and dexamethasone for patients with al amyloidosis following at least one prior line of therapy - DE
Zentrum für Innere Medizin (Krehl-Klinik)

Medizinische Klinik V - Hämatologie, Onkologie und Rheumatologie

ReDox: A Randomized Phase II/III Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy - DE
Zentrum für Innere Medizin (Krehl-Klinik)

Medizinische Klinik V - Hämatologie, Onkologie und Rheumatologie

A phase 2 study of Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis -DE
Zentrum für Innere Medizin (Krehl-Klinik)

Medizinische Klinik V - Hämatologie, Onkologie und Rheumatologie

PRESIDIO: A Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients with Active Polymyositis or Dermatomyositis
Institution: Information not provided - DE

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Dermatomyositis - DE
Institution: Information not provided - DE

EMERALD: A Two-cohort, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, PK and PD, of Emapalumab in Children and Adults With MAS in Still's Disease or With MAS in Systemic Lupus Erythematous - DE
Institution: Information not provided - DE

The RECLAIIM Study: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM) - DE
Charité - Universitätsmedizin Berlin

wiRASSc: Influence of serial locoregional water-filtered infrared A radiation in addition to a multimodal standard therapy for systemic sclerosis and Raynaud's syndrome of the hands
Kerckhoff-Klinik GmbH

Abteilung für Rheumatologie und klinische Immunologie

SENSCIS (TM) Extension: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) - DE
Medizinische Hochschule Hannover

Klinik für Pneumologie

The RECLAIIM Study: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM) - DE
Universitätsklinikum Essen

Klinik für Neurologie

The RECLAIIM Study: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM) - DE
Universitätsklinikum Köln

The RECLAIIM Study: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM) - DE
Universitätsklinikum Münster

A Phase II/III, randomized, double-blind, placebo-controlled study and open active-treatment extension study to assess the efficacy and safety of the branch chain amino acids (BCAAs) in polymyositis and dDermatomyositis.
Institution: Information not provided - JP

Randomized, double-blind, parallel group comparison trial of Tocilizumab for colchicine-resistant familial Mediterranean fever
Institution: Information not provided - JP

Clinical trial of rituximab in interstitial lung disease secondary to systemic sclerosis
Institution: Information not provided - JP

SENSCISTM- ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) - IE
St. Vincent's University Hospital

CF Clinic

EYEGUARD-B: A Randomized, Double-masked, Placebo-controlled Study of the Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (Phase III)
Institution: Information not provided - IT

Studio di fase 1/2 in aperto su Melflufen e Desametasone in pazienti con Amiloidosi AL che seguono almeno una precedente linea di terapia - IT
Institution: Information not provided - IT

Studio multicentrico di fase 2/3, in doppio cieco, randomizzato, controllato con placebo, a gruppi paralleli per valutare l'efficacia e la sicurezza di ravulizumab in partecipanti adulti affetti da dermatomiosite
Institution: Information not provided - IT

Studio di Fase III nella Dermatomiosite giovanile all'esordio: prednisone verso prednisone più ciclosporina verso prednisone più metotrexate
IRCCS Istituto G. Gaslini - Ospedale Pediatrico

U.O. Pediatria II

Studio multicentrico randomizzato di fase III del Melphalan e Dexamethasone (MDex) vs Bortezomib, Melphalan e Dexamethasone (BMDex) nel trattamento di pazienti con Amiloidosi.
Fondazione IRCCS Policlinico San Matteo

Laboratorio di Biotecnologie e Tecnologie Biomediche

Studio randomizzato di fase II/III di doxiciclina rispetto alla terapia di supporto standard nei pazienti con amiloidosi cardiaca AL di nuova diagnosi sottoposti a terapia a base di bortezomib - IT
Fondazione IRCCS Policlinico San Matteo

Dipartimento di Medicina Molecolare

ASTIS: Sperimentazione multicentrica di trapianto autologo di cellule staminali in pazienti affetti da Sclerodermia (Fase III)
AOU Careggi

Dipartimento di Biomedicina

IMMEDIATE: Intravenous immunoglobulins as early treatment in newly diagnosed idiopathic inflammatory myopathies: a pilot study
Amsterdam UMC, locatie AMC

Afdeling Neurologie

A Phase II, Randomized, Multi-center, Placebo-controlled, Double-blind Study to Investigate the Safety of GS-248, and Efficacy on Raynaud's Phenomenon (RP) and Peripheral Vascular Blood Flow, in Subjects With Systemic Sclerosis (SSc) - NL
Institution: Information not provided - NL

The MANUS Trial: Mesenchymal Stromal Cells for Angiogenesis and Neovascularisation in Digital Ulcers of Systemic Sclerosis (Phase II)
UMC Utrecht - Universitair Medisch Centrum Utrecht

Afdeling Nefrologie

EYEGUARD-B: A Randomized, Double-masked, Placebo-controlled Study of the Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (Phase III) - PT
Institution: Information not provided - PT

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Dermatomyositis -GB
Institution: Information not provided - GB

RBHIPF004 - A randomized, double blind controlled trial comparing rituximab against intravenous cyclophosphamide in connective tissue disease associated interstitial lung disease
National Heart and Lung Institute, Imperial College, Royal Brompton Campus

Interstitial Lung Disease Unit

SENSCISTM- ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD)GB
Institution: Information not provided - UK

An open-label, phase 1/2 study of melflufen and dexamethasone for patients with al amyloidosis following at least one prior line of therapy - ES
Hospital Clínic de Barcelona

Servicio de Hematología

RECLAIIM: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM) -ES
Institution: Information not provided - ES

Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis -ES
Institution: Information not provided - ES

AFFIRM-AL: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis - ES
Institution: Information not provided - ES

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Dermatomyositis -ES
Institution: Information not provided - ES

VALOR: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults with Dermatomyositis -ES
Institution: Information not provided - ES

An open label, long-term extension study to investigate the safety of PF-06823859 administered to adult participants >=18 and <=80 with active dermatomyositis -ES
Hospital Universitario 12 de Octubre

A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis - US
University of Pennsylvania

Perelman School of Medicine

Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis
Institution: Information not provided - US

A Phase II Multi-center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation With Post Transplant Maintenance for the Treatment of Systemic Sclerosis
University of Washington

EMERALD: A Two-cohort, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, PK and PD, of Emapalumab in Children and Adults With MAS in Still's Disease or With MAS in Systemic Lupus Erythematous - SE
Institution: Information not provided - SE

EYEGUARD-B: A Randomized, Double-masked, Placebo-controlled Study of the Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (Phase III) - TN
Institution: Information not provided - TN

EYEGUARD-B: A Randomized, Double-masked, Placebo-controlled Study of the Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (Phase III) - TR
Institution: Information not provided - TR

A Multi-centre, Double-blind, Placebo Controlled, Proof of Concept Study to Evaluate the Efficacy and Tolerability of BAF312 in Patients With Polymyositis
Institute of Genomic Medicine and Rare Disorders, Semmelweis University

Genetics Laboratory

A Double-blind, Randomised, Placebo-controlled Trial Evaluating the Effect of BI 655064 Administered as Sub-cutaneous Injections, on Renal Response After One Year of Treatment, in Patients With Active Lupus Nephritis (Phase 2) - AT
Institution: Information not provided - AT

BRAVE I: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus - AT
Institution: Information not provided - AT

SLE-BRAVE-X: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE) - AT
Institution: Information not provided - AT

SELECT-GCA: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Giant Cell Arteritis (Phase 3) - AT
Institution: Information not provided - AT

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Giant Cell Arteritis (Phase 3) - AT
Institution: Information not provided - AT

PHOENYCS GO: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus (Phase 3) - AT
Institution: Information not provided - AT

A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis (Phase 2) - AT
Institution: Information not provided - AT

A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Efavaleukin Alfa in Subjects with Active Systemic Lupus Erythematosus With Inadequate Response to Standard of Care Therapy - AT
Institution: Information not provided - AT

A Phase II, randomised, placebo-controlled, double-blind, parallel-group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with early progressive diffuse cutaneous systemic sclerosis - AT
Institution: Information not provided - AT

GOOD-IDES: An Open-Label Phase II Study in Anti-GBM Disease (Goodpasture's Disease) With Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS - AT
Allgemeines Krankenhaus der Stadt Wien

Klinische Abteilung für Nephrologie und Dialyse

A Phase 2, Randomized, Double-blind Placebo-controlled Study to Test the Efficacy and Safety of KPL-301 in Giant Cell Arteritis - BE
Institution: Information not provided - BE

NOVESA study: A Phase 2a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, and tolerability of orally administered GLPG1690 for 24 weeks in subjects with systemic sclerosis - BE
Ghent University Hospital - UZ Gent

Department of Rheumatology

A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis - BE
UZ Leuven - Campus Gasthuisberg

UZ Leuven

RESOLVE-1 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis-CA
Institution: Information not provided - CA

METOGiA: MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial
CHU Dijon Bourgogne - Hôpital François Mitterrand

Service de médecine interne et immunologie clinique

A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB IN SUBJECTS WITH GIANT CELL ARTERITIS (Phase III) - FR
Institution: Information not provided - FR